Association of remnant cholesterol with cardiovascular disease events in patients with diabetes: a dose-response systematic review and meta-analysis of adjusted models.

Nutr Metab Cardiovasc DisApr 17, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Reza Eshraghi, Ashkan Bahrami, Mohammadreza Kosari et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the relationship between remnant cholesterol (RC) levels and cardiovascular disease (CVD) events in individuals with diabetes, analyzing data from 2,276,576 participants across fifteen studies. The findings indicate that higher RC levels are associated with increased cardiovascular events, with a pooled hazard ratio for major adverse cardiovascular events (MACE) of 1.64 (95% CI: 1.16-2.30).

Key findings

  • Pooled HR for MACE was 1.64 (95% CI: 1.16-2.30), indicating higher risk with increased RC.
  • Pooled HR for revascularization was 1.44 (95% CI: 1.22-1.70).
  • Pooled HR for ischemic stroke was 1.12 (95% CI: 1.01-1.24).
  • Dose-response analysis showed significant relationships for MACE (p < 0.0001) and myocardial infarction (p = 0.0008).

Why it matters

Understanding the association between remnant cholesterol and cardiovascular events in diabetic patients can enhance risk stratification and inform clinical decision-making regarding lipid management and monitoring.

Source

Published in Nutr Metab Cardiovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.